The hormone erythropoietin (EPO), which is synthesized in the kidney or liver of adult mammals, controls erythrocyte production and is regulated by the stress-responsive transcription factor hypoxia-inducible factor-2 (HIF-2). We previously reported that the lysine acetyltransferase CREB-binding protein (CBP) is required for HIF-2a acetylation and efficient HIF-2-dependent EPO induction during hypoxia. We now show that these processes require acetate-dependent acetyl CoA synthetase 2 (ACSS2). In human Hep3B hepatoma cells and in EPO-generating organs of hypoxic or acutely anemic mice, acetate levels rise and ACSS2 is required for HIF-2a acetylation, CBP-HIF-2a complex formation, CBP-HIF-2a recruitment to the EPO enhancer and efficient induction of EPO gene expression. In acutely anemic mice, acetate supplementation augments stress erythropoiesis in an ACSS2-dependent manner. Moreover, in acquired and inherited chronic anemia mouse models, acetate supplementation increases EPO expression and the resting hematocrit. Thus, a mammalian stress-responsive acetate switch controls HIF-2 signaling and EPO induction during pathophysiological states marked by tissue hypoxia.
Oxygen deprivation induced by hypoxia activates stress responses, one of which, in vertebrates, is increased red blood cell production or erythropoiesis 1, 2 . The discovery of EPO, an endocrine growth factor synthesized in the adult kidney and liver, began with elegant physio logical experiments demonstrating an erythropoiesispromoting bloodborne factor, continued with the characterization and purifica tion of the EPO protein and culminated with cloning of the EPO gene 3 . Mapping of the hypoxiaresponsive enhancer region in the EPO gene identified a molecular handle subsequently used to purify HIF1 (ref. 4 ), a sentinel regulator of the mammalian hypoxia response.
HIF1 is a heterodimeric stressresponsive transcription factor comprising an oxygensensitive α subunit and an oxygeninsensitive β subunit. During hypoxia, HIF1α is regulated in a unique manner 5 through inhibition of two classes of oxygendependent enzymes: prolyl hydroxylases that decrease HIF1α stability and an asparagine hydroxylase (factor inhibiting HIF1, FIH1) that prevents coactivator-HIF1α interactions 6 . Mining of the human genome led to the discovery of HIF2α, the second vertebrate HIF family member to be identified [7] [8] [9] . Although HIF2α is structurally similar to HIF1α, genetic ablation studies in cells and mice indicated that HIF2α, rather than HIF1α, is the key regulator of endocrine EPO [10] [11] [12] [13] [14] [15] .
HIF2α undergoes the same oxygendependent posttranslational modifications as HIF1α. However, although increases in HIF2α protein levels during hypoxia are only modest in comparison to increases in HIF1α protein levels in some cell lines, HIF2 signaling nevertheless is robust, which suggests that posttranslational mecha nisms other than protein stability play a major role in HIF2 signaling. Indeed, acetylation and deacetylation of HIF2α are required for efficient HIF2 signaling during hypoxia in Hep3B cells and in mice.
HIF2α acetylation is mediated by the lysine acetyltransferase and transcriptional coactivator CBP, which also provides a molecular plat form for stable CBP-HIF2α complex formation, whereas sirtuin1 (SIRT1) is a specific deacetylase for acetylated HIF2α that facilitates reengagement of HIF2α by CBP 13, 16 . Notably, the lysine acetyltrans ferase and transcriptional coactivator p300, which is closely related to CBP, does not acetylate HIF2α and is a minor component of HIF2 signaling in Hep3B cells and in mouse liver, yet p300 also complexes with HIF2α during hypoxia 16 . We were interested in further exploring these differences in biochemical properties and signaling function for CBP and p300 in HIF2α-regulated signal transduction.
RESULTS

ACSS2 controls HIF-2 signaling in hypoxic cells
We first defined the kinetics of HIF2α acetylation as well as CBP-HIF2α and p300-HIF2α complex formation in Hep3B cells during hypoxia. Following hypoxia onset, the amount of HIF2α acetylation and CBP-HIF2α complexes peaked early (2 h), whereas p300-HIF2α complexes formed late (8 h) ( Fig. 1a,b) . Because CBP-HIF2α complex formation requires both CBP enzymatic (i.e., acetyltransferase activity) and HIF2α substrate (i.e., lysine residues) determinants of the acetylation reaction 16 , we reasoned that the CBP acetylation reaction itself might be the primary determi nant of CBP-HIF2α complex formation. We further reasoned that changes in availability of acetyl CoA, the other required substrate in the CBP acetylation reaction, might control dynamic CBP-HIF2α interactions during hypoxia.
Acetyl CoA is synthesized de novo by pyruvate dehydrogenase, ATP citrate lyase (ACLY) or acetatedependent acetyl CoA synthetases (ACSSs). During hypoxia, pyruvate dehydrogenase is inactivated by the HIF1 target gene product pyruvate dehydrogenase kinase 17, 18 , whereas ACLY, a major source of cytosolic acetyl CoA, remains active 19 . ACSS1 generates mitochondrial acetyl CoA 20 , and ACSS2 generates cytosolic acetyl CoA [21] [22] [23] . Because ACSS2 and ACLY may reside in the nucleus 24 , we asked whether their subcellular locations, as well as those of CBP, SIRT1 and HIF2α, change during hypoxia in Hep3B cells using subfractionation of cells following exposure to basal (normoxia) or hypoxic conditions (Fig. 1c) . ACSS2 localized to the nucleus during early hypoxia (2 h), coincident with peak acetyla tion and CBP-HIF2α complex formation, but to the cytosol during late hypoxia (8 h) when these processes have returned to basal levels. with Holm-Sidak correction (****P ≤ 0.0001). The increase in acetate levels as well as role of Acss2 in endogenous Hif-2α acetylation and induction of Epo gene expression in hypoxia-exposed mice was confirmed by least one additional experiment.
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In contrast, ACLY was mostly cytosolic, and the relative distribution between the cytosol and nucleus remained unchanged during both early and late hypoxia. Moreover, CBP was restricted to the nucleus, whereas HIF2α was present in both the cytosol and nucleus; their distribution did not change appreciably during hypoxia. Nuclear SIRT1 levels increased during hypoxia, which may be a result of both an increase in SIRT1 mass during hypoxia 25 and indirect passenger effects due to interactions of SIRT1 with its targets. The dynamic behavior of ACSS2 with regard to its subcellular location during hypoxia led us to consider it a candidate acetyl CoA generator for CBPmediated HIF2α acetylation and therefore a reg ulator of HIF2 signaling. We hypothesized that acetate generated by hypoxic cells 26 might function as a biochemical cue to activate ACSS2. Indeed, cellular acetate levels increased and peaked by an early (2 h) hypoxia time point and then declined to basal levels ( Fig. 1d) . As we have shown previously 16 , acetylation of HIF2α is dependent upon CBP and not p300 ( Fig. 1e) . Knockdown of ACSS2 by transient expression of siRNA, but not of ACSS1 or ACLY by a similar approach, eliminated HIF2α acetylation and CBP-HIF2α complex formation in early hypoxia, and there was a shift to p300-HIF2α complex for mation ( Fig. 1e,f) . Finally, using semiquantitative realtime PCR measurements of Hep3B cells exposed to normoxia or hypoxia in conjunction with siRNA knockdown, we found that ACSS2, but not ACSS1 or ACLY, was required for efficient induction of the HIF2 target gene EPO during hypoxia ( Fig. 1g) .
We next investigated whether ACSS2 is required for HIFα or coac tivator (p300 or CBP) recruitment in Hep3B cells using chromatin immunoprecipitation (ChIP) assays ( Supplementary Fig. 1a ). HIF2α and HIF1α recruitment to the EPO enhancer was evident during early (2 h) and late (8 h) hypoxia. ACSS2 knockdown eliminated HIF2α but not HIF1α recruitment to the EPO enhancer and also eliminated CBP but not p300 recruitment to this region. Furthermore, as assessed by sequential ChIP, ACSS2 knockdown eliminated HIF2α recruitment of CBP to the EPO enhancer during early (2 h) hypoxia but did not affect HIF2α recruitment of p300 during late (8 h) hypoxia ( Supplementary  Fig. 1b ). Conversely, ACSS2 knockdown eliminated CBP recruitment of HIF2α to the EPO enhancer during early (2 h) hypoxia but did not affect p300 recruitment of HIF2α ( Supplementary Fig. 1c ).
HIF1α also regulates EPO gene expression in Hep3B cells exposed to hypoxia 16 . However, ACSS2 knockdown did not affect HIF1α recruitment of CBP or p300 to the EPO enhancer or to the promoter of the HIF1-selective target gene PGK1 in Hep3B cells during hypoxia ( Supplementary Fig. 1d,e ). ACSS2 knockdown also had no effect on HIF1α or HIF2α recruitment to the proximal promoter region of a non-hypoxiaresponsive gene, RPL13A (Supplementary Fig. 1f and SLC2A1), by HIF2α only (MMP9) or by HIF1α only (PGK1) (Supplementary Fig. 2a-c) . For target genes regulated in part or solely by HIF2α, knockdown of ACSS2, but not of ACSS1 or ACLY, blunted induction following hypoxia exposure ( Supplementary  Fig. 2d ). In contrast, induction of a HIF1α selective target gene, PGK1, was unaffected by knockdown of any of these acetyl CoA generators ( Supplementary Fig. 2e ).
Acss2 regulates hypoxia-induced renal Epo expression in mice
To assess the physiological role of Acss2 in Epo regulation, we studied homozygous Accs2knockout mice on a mixed genetic background containing a deletion allele of the mouse Acss2 gene ( Supplementary  Fig. 3a ). Wildtype but not knockout mice demonstrated Acss2 immunoreactivity in the cortex and medulla of the kidney as well as in the liver parenchyma ( Supplementary Fig. 3b,c) . Following hypoxia exposure of mice in a controlled environmental chamber, acetate lev els in both wildtype and Acss2knockout kidney increased by 2 h and remained elevated ( Fig. 2a ). Hif2α isolated from kidneys of hypoxia exposed mice was acetylated on lysine residues in an Acss2dependent manner ( Fig. 2b) . Hypoxia exposure resulted in Hif2α recruitment to the Epo enhancer in wildtype but not Acss2knockout kidney, and sequential ChIP revealed that Cbp, but not p300, was present when Hif2α occupied the Epo enhancer ( Fig. 2c) .
We next asked whether Cbp-Hif2α complex formation at the Epo enhancer in mouse kidney during hypoxia correlates with Epo gene expression. Similarly to mice with global Hif2α knockout 11 , Epo mRNA expression in kidney of Acss2knockout mice was mark edly blunted after hypoxia exposure ( Fig. 2d) , as was the increase in plasma Epo protein levels that we observed in wildtype mice after 16 h of hypoxia exposure ( Fig. 2e ). However, in this setting of shortterm hypoxia (16 h), we did not observe an increase in red blood cell mass following the initial rise in hematocrit levels during the early (2 h) hypoxia phase, an immediate physiological response 27 observed in both wildtype and Acss2knockout mice ( Supplementary Fig. 3d ).
Acute anemia induces Acss2-dependent Hif-2 signaling in mice
To determine whether Acss2-Hif2 signaling is relevant under pathophysiological states marked by more prolonged periods of tis sue hypoxia, we used phenylhydrazine (PHZ) to induce hemolytic anemia. PHZ injection resulted in a comparable degree of severe anemia by 4 d in wildtype and Acss2knockout mice ( Fig. 3a) . Recovery of Acss2knockout mice took substantially longer (18 d) than that of wildtype mice (9 d), consistent with an effect of reduced plasma Epo levels in Acss2knockout relative to wildtype mice at the hematocrit nadir ( Fig. 3b) .
Acetate levels at the anemia nadir increased to comparable levels in wildtype and Acss2knockout kidney and liver ( Fig. 3c,d) . Hif2α acetylation increased in kidney and liver of severely anemic wildtype mice but was undetectable in Acss2knockout mice ( Fig. 3e,f) . Finally, Epo mRNA levels were markedly induced in kidney and liver of anemic wildtype mice but were only slightly elevated in Acss2 knockout mice ( Fig. 3g,h) . The absence of Acss2 did not reduce The effect of acetate supplementation on HIF-2α acetylation and CBP-HIF-2α complex formation as well as its dependence upon ACSS2 were confirmed by at least one additional independent experiment.
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An acetate switch regulates CBP-HIF-2 interactions in cells
We reasoned that acetate generated by hypoxic cells could trigger CBP mediated HIF2α acetylation. Indeed, HIF2α acetylation increased in Hep3B cells incubated with conditioned medium of Hep3B cells exposed to hypoxia for 2 h or with acetatesupplemented medium, but not in Hep3B cells incubated with medium supplemented with the shortchain fatty acids (SCFAs) butyrate or propionate ( Fig. 4a and Supplementary Fig. 4a ). HIF2α acetylation induced by acetate treatment required ACSS2 and CBP, as shown following transient knockdown with siRNA ( Fig. 4b) . Similarly, we observed CBP-HIF 2α complex formation in cells incubated with early (2 h) hypoxiaconditioned medium or with acetatesupplemented medium, but not in cells incubated with medium supplemented with other SCFAs ( Fig. 4c and Supplementary Fig. 4b ). Stable ACSS2dependent CBP-HIF 2α complex formation in Hep3B cells induced by acetate required ACSS2 as well as SIRT1 and CBP, as shown following transient knock down with siRNA ( Fig. 4d,e ), which is similar to requirements under hypoxia 16 . Similarly to hypoxia exposure, acetate supplementation resulted in ACSS2 nuclear localization ( Fig. 4f) , but supplementation with the other SCFAs did not have this effect. Finally, ACSS2 knock down blocked acetateinduced HIF2α acetylation ( Fig. 4g) . This loss of acetylation was rescued by expression of an siRNAresistant wildtype ACSS2 cDNA, but not of an siRNAresistant deletion mutant ACSS2 cDNA ( Fig. 4g) . Acid exposure has been implicated in the release of acetate from cells as well as in activation of HIF2 signaling through increases in HIF2α protein levels 28, 29 . Exposure of Hep3B cells to hypoxia, hypoxiaconditioned medium or exogenous acetate all resulted in elevated intracellular acetate levels, but only the culture medium of Hep3B cells treated with hypoxia had altered acidity ( Supplementary  Fig. 4c ). However, we do not consider the minor changes in the acidity of hypoxiaconditioned medium to be either biologically or statisti cally meaningful. CBP-HIF2α complex formation was evident in extracts prepared from Hep3B cells exposed to early (2 h) hypoxia and was absent in extracts from cells in which ACSS2 had been depleted following ACSS2 knockdown; however, it was restored in these latter extracts upon addition of acetyl CoA (Supplementary Fig. 4d ). Although normally absent in ACSS2replete, late (8 h) hypoxia cell extracts, CBP-HIF2α complex formation was induced in vitro in such extracts by supplementation with either acetyl CoA or with acetate and ATP, cofactors required by ACSS2 21 whose levels decrease during hypoxia 30 (Supplementary Fig. 4e ).
ACSS2 signaling in cells requires intact HIF-2 acetylation
To ascertain whether HIF2α acetylation and CBP-HIF2α complex formation induced by acetate requires HIF2α lysine residues that are acetylated following hypoxia exposure, we first generated npg knockdown/rescue Hep3B cells in which endogenous HIF2α was reduced by stable expression of shRNA while simultaneously expressing either an shRNAresistant HIF2α cDNA with intact lysine residues that are acetylated during hypoxia (K3 HIF2α) or an shRNAresistant HIF2α cDNA with arginines substituted for these lysine residues (R3HIF2α) 13 . We then exposed the K3 and R3 HIF2α knockdown/rescue Hep3B cells to hypoxia or to medium supplemented with each SCFA. The K3 but not R3 version of HIF2α was acetylated ( Fig. 5a,b) and formed a complex with CBP ( Fig. 5c,d ) during hypoxia or after acetate supplementation. We next determined the role of the HIF2α lysine residues that are acetylated in EPO gene expression following hypoxia exposure using realtime PCR measurements of cDNA prepared from K3 and R3 HIF2α knockdown/rescue Hep3B cells exposed to hypoxia. We also deter mined the contribution of ACSS2 to EPO induction in the K3 and R3 HIF2α knockdown/rescue Hep3B cells exposed to hypoxia by using transient knockdown of ACSS2 with siRNA. EPO mRNA induction was blunted in R3 HIF2α-rescued cells compared to K3 HIF2αrescued cells (Fig. 5e) . Moreover, whereas EPO mRNA induction was markedly reduced by ACSS2 knockdown in K3 HIF2α-rescued cells, ACSS2 knockdown had no effect in R3 HIF2α-rescued cells (Fig. 5e) . These results suggest that the effect of ACSS2 on HIF2 signaling is mediated through acetylation of the lysine residues present in the K3 but not R3 version of HIF2α.
Acetate facilitates recovery from anemia
To determine whether daily treatment with SCFAs affects recovery of mice from acute anemia, we administered either glyceryl triesters of acetate (GTA), butyrate (GTB) or propionate (GTP) by oral gavage or buffered solutions of acetate, butyrate or propionate by intraperi toneal (i.p.) injection to wildtype CD1 mice beginning 4 d following induction of PHZinduced anemia; treatment was continued in all mice until wildtype anemic mice receiving vehicle treatment had recovered to baseline hematocrit levels . Erythropoiesis in acutely ane mic wildtype CD1 mice was augmented after supplementation with oral or i.p. acetate but not with butyrate or propionate and resulted in a more rapid return to baseline hematocrit levels (Fig. 6a) . Acetate supplementation also sped recovery from PHZinduced anemia in wildtype but not Acss2knockout mice on a mixedstrain genetic background (Fig. 6b) .
Hematocrit levels of anemic CD1 mice treated with GTA returned to normal levels earlier (day 6 of treatment) as compared to anemic mice receiving vehicle (day 9 of treatment) (Supplementary Fig. 5a ). Despite an initial overshoot in the hematocrits of anemic mice that were continued on GTA supplements (day 9 of treatment), hematocrit levels returned to baseline shortly thereafter (day 12 of treatment), even with continued GTA administration. Reticulocyte levels, which were elevated in acutely anemic mice (day 4 after PHZ; day 0 of treatment), returned to normal more rapidly in GTAtreated mice as compared npg to vehicletreated mice (Supplementary Fig. 5b ). We also observed increased (kidney) or prolonged (liver) Hif2α acetylation after GTA treatment of acutely anemic mice ( Supplementary Fig. 5c,d) .
With respect to downstream effects on Hif2 signaling in mice, GTAtreated anemic CD1 mice had a greater increase in Epo mRNA levels in kidney and liver than did vehicletreated anemic mice (days 3 and 6 of treatment), and the Epo mRNA levels in GTA-treated anemic mice remained elevated for 3 d longer (to day 6 of treatment) ( Supplementary Fig. 6a,b) . Nevertheless, soon after the hematocrit levels of GTAtreated anemic mice returned to normal (day 6 of treatment), Epo mRNA levels also returned to basal levels in kidney and liver (day 9 of treatment) and remained so despite continued GTA administration (days 12 and 16 of treatment). Expression of the Hif1 target gene Pgk1 in kidney or liver did not differ between GTAtreated and vehicletreated mice ( Supplementary Fig. 6a,b) .
We also examined whether acetate supplementation affects eryth ropoiesis in two other settings: an acquired chronic anemia model, in which partial nephrectomy induces chronic renal failure (CRF mice) 31, 32 ; and a genetic chronic anemia model, doubleheterozygous (DH) Kitmutant mice, which are anemic as a result of different muta tions in each Kit allele 33, 34 . Following nephrectomy, CRF mice were divided into three groups (A, B and C) with nearly equivalent mean hematological (hematocrit) and blood chemistry (blood urea nitrogen, creatinine) parameters (Supplementary Data Set) and were treated with either vehicle (A), cyclical acetate (B) or SCFAs (C). For the SCFAs, supplementation with acetate, but not butyrate or propionate, increased resting hematocrit levels in both CRF and DH Kitmutant mice (Fig. 6c,d) . Acetate treatment resulted in increased hematocrit levels in CRF mice (i.e., mice after nephrectomy) or DH Kitmutant mice, but not in wildtype mice (Supplementary Fig. 7a,e ). Acetate treatment also led to increased reticulocyte counts in CRF mice but instead led to decreased reticulocyte counts in DH Kitmutant mice; this treatment had no effect on reticulocyte counts of wildtype mice (Supplementary Fig. 7b,f) . Acetate treatment increased renal Epo mRNA levels in both CRF and DH Kitmutant mice ( Supplementary  Fig. 7c,g) . Finally, acetate treatment resulted in elevated acetate levels in kidneys of all mice: CRF, DH Kitmutant and wildtype mice ( Supplementary Fig. 7d,h) .
We next asked whether the physiological effect of acetate treatment on Epo expression would be maintained if administered on a cyclical basis. We did so by interspersing an acetatefree interval between two cycles of 2week acetate supplementation treatments. Treatment of either CRF or DH Kitmutant mice with acetate in this cyclical man ner resulted in increased hematocrit levels (Fig. 6e,f ) that paralleled similar increases in plasma Epo protein ( Supplementary Fig. 8a,b) , whereas cessation of acetate supplementation reversed the increases in both hematocrit and plasma Epo protein levels. Finally, cyclical acetate treatment resulted in increased acetylated Hif2α protein levels in kidney of CRF or DH Kitmutant mice but not in that of wildtype mice (Supplementary Fig. 8c,d) .
DISCUSSION
Although EPO administration is an effective treatment for anemia, therapies that maintain physiological EPO regulation may reduce the deleterious side effects associated with bolus EPO treatment, including hypertension, thrombosis and possibly accelerated malignancies [35] [36] [37] . HIF2, a key regulator of endogenous EPO gene expression, may be a particularly efficacious target. A major finding from this study is that acetate, generated during hypoxia or anemia, is a signaling molecule used by a specific acetyl CoA generator, ACSS2, to regulate interactions of HIF2α with its selective acetyltransferase and coactivator, CBP. Recruitment of CBP-HIF2α complexes to the EPO enhancer occurs in parallel with CBP-HIF2α complex formation in cells during early hypoxia and also depends upon ACSS2. Notably, at a later phase of hypoxia, CBP and HIF2α remain associated with the EPO enhancer but not with each other, suggesting that the 'enhanceosome' containing CBP-HIF2α assembled at the EPO enhancer and likely at other HIF2 target genes undergoes further remodeling as hypoxia progresses.
The exact origin of the acetate that is generated during hypoxia and anemia is unknown. The liver generates endogenous acetate 38 under normal physiological conditions; a similar process has not been reported for kidney. The kidney and the liver exhibit zonal hypoxia, which places certain anatomical regions of these organs at risk to further changes in oxygen concentration 39, 40 . Acetate and acetyl CoA pools in cells rapidly cycle [41] [42] [43] , so perturbations of this cycle during hypoxia and anemia may facilitate transient increases in acetate levels in the kidney and liver 44 . Histone deacetylation in a markedly acidic environment results in acetate release 28 , although this does not appear relevant in this study. Increased SCFA levels may impair acetate utilization 45 or uptake 46 and thereby theoretically result in increased extracellular acetate concentrations. However, we found that SCFAs other than acetate do not trigger the ACSS2dependent responses of HIF2α acetylation and CBPHIF2α complex formation. ACSS2 is a proposed acetate generator 26 in cancer cells but is likely to be a minor source of acetate in normal cells, as acutely hypoxic or anemic wildtype and Acss2knockout mice have similar acetate levels in kidney and liver.
Changes in intermediary metabolism during hypoxia initiate ACSS2 activity but also terminate its action as hypoxia continues. During early (2 h) hypoxia in Hep3B cells, HIF2α acetylation, as well as CBP-HIF2α complex formation, which occurs via binding of HIF2α to CBP independent of HIF2α's carboxyterminal activation domain, is stimulated by increased acetate levels and is regulated by ACSS2. During late (8 h) hypoxia, acetate levels return to baseline and ATP levels are likely to decrease, limiting ACSS2 activity. In addition, FIH1 is inactive during late hypoxia [47] [48] [49] , implying that carboxyterminal activation domain-dependent recruitment of p300 can commence.
The molecular and biochemical effects of acetate supplementa tion include increased HIF2α acetylation, EPO mRNA levels and plasma EPO protein levels, resulting in an accelerated recovery from acute anemia. Continued acetate treatment has no further effect on hematocrit once it has recovered to normal levels, indicating proper functioning of the homeostatic mechanisms that control hematocrit under these conditions. Thus, acetate augmentation of HIF2 signaling in whole animals requires not only ACSS2 but also the concomitant presence of hypoxemia. Whether this requirement for hypoxemia reflects a need for the inactivation of prolyl hydroxylases or FIH1 or for the production of other factors activated during anemia 50 remains to be determined.
Acetate supplementation may be useful in treating acute anemia in civilian and military scenarios and for treating patients who have faithbased objections to blood transfusions 51 . Chronic anemia asso ciated with impaired EPO generation due to reduced HIF2 signaling may also be affected by the acetate switch, and acetate may already be unwittingly used therapeutically. Patients with endstage renal disease often have anemia as well as blunted EPO production 11, 13 and are dialyzed thrice weekly with an acetatecontaining dialysate that transiently increases plasma acetate levels 52, 53 . Patients with end stage renal disease transitioned to an acetatefree dialysate 54 exhibit npg increased darbepoetin and iron requirements 55 , consistent with the notion that HIF2 signaling is impaired in at least a subset of such patients. The ability of acetate treatment to increase EPO production in DH Kitmutant mice suggests that acetate may also be effective in treating genetic anemia disorders associated with impaired EPO but intact HIF2 signaling, particularly because increasing endogenous EPO levels in such cases may augment erythroid progenitor cell production and erythrocyte development 56 .
By increasing levels of acetatederived lipids 21 that are used for myelin synthesis, acetate supplementation therapy has been proposed for treating neuropathophysiological states such as traumatic brain injury 57 . ACSS2 may also be involved in this setting, as traumatic brain injury, which causes tissue ischemia and hypoxia, results in ACSS2 nuclear localization in astrocytes 57 . HIF2α is also expressed in astrocytes, where it regulates EPO gene expression and may alle viate neurological injury 58 . The broad distribution of ACSS2 in hepatocytes, as well as in the renal cortex and medulla, may signify an additional role of ACSS2-HIF2 signaling in the response to ischemic injury through regulation of cytoprotective factors 59, 60 . Whether ACSS2 plays a protective role in the injury response of vital organs is a topic for future studies.
METHODS
Methods and any associated references are available in the online version of the paper.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
ONLINE METHODS
Cell culture. We maintained Hep3B cells (Cat. No. HB8064, ATCC, Manassas, VA) in complete DMEM medium (Cat. No. SH30022, HyClone, Logan, UT), 10% FBS (FBS; Cat. No. F4135, Sigma) with penicillin (100 U mL -1 )/strep tomycin (100 µg mL -1 ) (Cat. No. 15140148, Gibco BRL, Carlsbad, CA) in a 5% CO 2 , 95% air incubator. We assayed cells periodically for mycoplasma. For passaging cells, we added 1 ml 0.25% Trypsin/2.21 mM EDTA/HBSS (Cat. No. 25052CI, Corning cellgro, Manassas, VA) to a freshly confluent 10cm plate and waited 1 min at room temperature. Trypsinized cells from one 10cm plate were added to complete medium (1:3 ratio) and replated into three 10cm plates. We used cells (unselected or selected) from between passages 15 and 25 in all experiments. For hypoxia treatments (1% O 2 , 5% CO 2 , 94% N 2 ), we maintained cells, replaced medium with deoxygenated medium and pre pared extracts within a humidified environmental chamber (Coy Laboratory Products, Inc., Grass Lake, MI). For shortchain fatty acid (SCFA) addition, we added the indicated sterile stocks of SCFAs (acetate, proprionate, butyrate) to complete medium (final concentration 0.5 mM) and harvested cells after the indicated time under normal oxygen conditions. Lentiviral generation. We previously described the wildtype (WT) acetylase sensitive (K3) and acetylaseinsensitive (R3; K385R, K685R, K741R) human HIF2α plasmids 13, 16 . All human HIF2α rescue cDNA constructs contained a carboxyterminal hemagglutinin (HA) epitope tag. We generated wildtype (WT) and mutant (MUT) Acss2 from a mouse Acss2 cDNA. MUT Acss2 cDNA, con structed by zipper PCR, contains a deletion that removes coding exons 3 through 7 in the Acss2 gene and the corresponding nucleotides in the Acss2 mRNA (nt 439898, RefSeq NM_019811.3). All Acss2 constructs contain an amino terminal V5 epitope tag. The MUT Acss2 cDNA generates a frameshifted mRNA encoding a truncated Acss2 protein that lacks the majority of predicted functional domains and is not detected by immunoblotting with antibody either to Acss2 or to the V5 epitope tag. We therefore consider this Acss2 deletion mutant cDNA a null mutant. The rescue human HIF2α and mouse Acss2 cDNAs contain silent mutations as detailed below that confer resistance to siRNA or shRNA directed against the endogenous human mRNA of interest.
The lentiviral knockdown constructs express multiple miR30 shRNAs 61 using Pol II promoters 62 for efficient knockdown. For knockdownonly studies (control and Acss2), lentiviral (LTV) shuttle expression vectors (derivatives of pLenti6/V5GW/lacZ, Invitrogen, that are neomycin instead of blasticidin resistant) harbor a firefly luciferase cDNA followed by a con catamer of four different shRNAs directed against the gene of interest. For knockdown/rescue studies, LTV shuttle expression vectors encode an siRNA/shRNAresistant mouse Acss2 or human HIF2α cDNA encom passing the translated portion followed by an IRES:firefly luciferase:shRNA concatamer cassette (WT and MUT Acss2) or an IRES:DsRed:shRNA concat amer cassette (K3 and R3 HIF2α). The seed sequences for the four human ACSS2 shRNAs are as follows: 5′GTAATAGCCATCCTGGTCCCGC3′, 5′AACTTGGTCACCTTGTATTTGT3′, 5′TGGTATGTGATCTGAGTGGTCT3′, 5′GTATCCAGGAAACTTCTTAAAG3′. The corresponding sequences for the siRNA/shRNAresistant mouse Acss2 cDNA with changes from the human ACSS2 mRNA indicated in lower case are as follows: 5′aTAgTAtCCgTCtTGaTCtctt3′, 5′AAtTTtGTgACtTTaTAcTTaT3′, 5′ctaTAgGTaATtTtgGTtGTtT3′, 5′aTAgCCtGGgAAtTTtTTgAAa3′. The seed sequences for the four human HIF2α shRNAs are based on previously designed siRNAs 10,63-65 and are as follows: 5′ACTGCTATCAAAGATGCTGTTC3′, 5′TCTGTGTCCATGG CGAAGAGCT3′, 5′TTCATACTCCAGCTGTCGCTTC3′, 5′TAAGTC TATCCGGGCTTACTAA3′ with this last shRNA targeting the 3′ untranslated region of the mRNA. The corresponding sequences for the siRNA/shRNA resistant human HIF2α cDNA with changes from the human HIF2α mRNA indicated in lowercase are as follows: 5′tgacgagTCgAAaATcgaaTTC3′, 5′TCaGTaTCCATcGCaAAcAatT3′, 5′cTCgTAtTCtAatTGcCttTTg3′.
We used the LTV packaging plasmid psPAX2 (Addgene plasmid 12260) and the envelope plasmid pMD2.G (Addgene plasmid 12259) in conjunction with the shuttle expression plasmids to generate lentivirus. We generated concentrated lentiviral stocks from a 10cm plate of HEK 293T cells cotransfected with 3 µg LTV shuttle expression vector, 2.25 µg plasmid psPAX2 and 0.75 µg pMD2G using Lipofectamine 2000 (Cat. No. 11668019, Invitrogen) using LentiX Concentrator (Cat. No. 631232, Clontech). We aliquoted the virus immediately and stored it at −80 °C until use.
Stable cell line generation. The day before transduction, we plated 2 × 10 5 Hep3B cells per well in 1 mL complete culture medium overnight in a 6well plate. On the day of transduction, we replaced medium with 1 mL of com plete medium with 10 µg mL -1 polybrene (Cat. No. 107689, Sigma, St. Louis, MO). We thawed lentiviral particles to room temperature, mixed gently and added to Hep3B cells (MOI = 30). After 12 h, we replaced culture medium with 2 mL of complete medium containing 400 µg mL -1 G418 (Cat. No. SV3006901, HyClone) and replaced it every 2 d until 1 week after all control cells died. We maintained the initially positiveselected cells in 100 µg mL -1 G418 for 2 weeks, harvested cells into a smaller dish until confluent, split cells at 1:3 ratio and grew them for at least ten passages under drug selection and then froze the cells down until use. For experiments, we thawed cells, main tained cells in 100 µg mL -1 G418, split cells 1:3 for at least three passages when growing exponentially, trypsinized cells lightly at room temperature and used cells in actual experiments without drug selection when freshly confluent. We used cells between passages fifteen and twentyfive passages from the initial drug selection. For transient lentiviral transduction knockdown (control, ACCS2)/rescue (WT and MUT Acss2) experiments, we added 100 µL of concentrated lenti viral preparations to a 60mm Hep3B plate, waited 6 h and then changed the medium to complete medium. After an additional 36 h, we performed the indicated experiment. For stable lentiviral transduction knockdown (control, HIF2α)/rescue (K3 and R3 HIF2α) experiments, we thawed, grew, split and used cells as described above. Experiments were performed without drug selection as described above.
Immunoblotting. We used 20 µg Hep3B wholecell extracts, 20 µg Hep3B nuclear or cytosolic extracts and 10 µg mouse kidney or liver extracts for immunoblotting 13, 16 . To prepare wholecell extracts from Hep3B cells, we used CytoBuster protein extraction reagent (Cat. No. 71009, Novagen, Gibbstown, NJ) with 1× protease inhibitor cocktail (Cat. No. P8340, Sigma, St. Louis, MO) and 1 mM PMSF (phenylmethylsulfonyl fluoride) (Cat. No. P7626, Sigma) and stored extracts at −80 °C until use. To prepare nuclear extracts from Hep3B cells, we used NEPER nuclear and cytoplasmic extraction reagents (Cat. No. 78833, Pierce, Rockford, IL) according to the manufacturer's protocol and stored extracts at −80 °C until use. To prepare tissue extracts from liver or kidney, we used CytoBuster protein extraction reagent with 1× protease inhibitor cocktail and 1 mM PMSF and stored extracts at −80 °C until use.
We used antibodies raised against the following antigens: npg Acetate measurements. For cellular acetate measurements, we plated Hep3B cells at 80% confluency as triplicate biological replicates in 60mm plates and grew them overnight in an incubator within the hypoxia workstation until the indicated time point. At the time of harvest, we aspirated off medium, added 1 mL icecold 0.1 N HCl and scraped cells. We transferred the lysate from each plate to an icecold microfuge tube and pelleted the cellular debris at 14,000 r.p.m., 4 °C, 10 min. We transferred 0.9 mL supernatant to a new, icecold microfuge tube and then adjusted the pH to 6.5-7.0 with 5 N NaOH. We determined acetate concentrations from freshly prepared extracts in duplicate using the Megazyme Acetic Acid Rapid Kit (Cat. No. KACETRM, Megazyme, Ireland).
For hypoxic mouse kidneys, we exposed wildtype and Acss2knockout mice to room air (21% O 2 ) or hypoxia (6% O 2 ) for 2 h and then euthanized mice under normoxic or hypoxic air mixtures to harvest kidney samples. For anemic mouse kidneys and livers, we euthanized mice under normoxic air mixtures to harvest kidney samples. To measure tissue acetate levels, we placed (~0.1 g) weighed, freezeclamped, powdered tissue into a cold microfuge tube on dry ice and slowly added 500 µL icecold 1 N perchloric acid. We slowly thawed the samples on ice and then followed with homogenization (PowerGen 700D, Fisher Scientific). We pelleted the homogenate at 14,000 r.p.m., 4 °C, 10 min. We transferred 0.5 mL supernatant to a new, icecold microfuge tube and then adjusted the pH to 6.5-7.0 with 10 N NaOH. We incubated the extract on ice for 30 min to precipitate proteins and then centrifuged at 14,000 r.p.m., 4 °C, 10 min. We transferred the supernatant to a new tube and assayed fresh as single measurements described above and normalized to the weight of tissue used. pH measurements (medium). For pH measurements of medium collected from cells housed using normal, hypoxiaconditioned or acetatesupplemented (0.5 mM final concentration) complete medium, we prepared Hep3B cells the day before treatment, 5 × 10 6 per 100mm plate, with a single plate for each treat ment. On the day of treatment, we replaced the complete DMEM containing 10% FBS and penicillin/streptomycin with the appropriate prewarmed medium (10 mL) and exposed the cells for 2 h as indicated. We collected the media into 15mL conical tubes and measured pH using a standard meter (Fisher Scientific, accumet Basic AB15 pH Meter) and electrode (LiquidFilled Polymer Body Combination Electrodes-MercuryFree accumet pH combination; Std. Size DoubleJunction Ag/AgCl reference) calibrated with pH (4, 7, 10) standards. The data obtained were single measurements.
Endogenous HIF-2a acetylation (cells).
We cultured Hep3B cells in a single 100mm plate in complete medium supplemented with 5 µM sirtinol plus 10 mM NAM for 6 h under either normoxia or hypoxia. For acetylation assays using wholecell extracts, we lysed cells with CytoBuster protein extraction reagent supplemented with 1× protease inhibitor cocktail, 1 mM PMSF, 10 mM NAM and 5 µM sirtinol. For acetylation assays with nuclear or cytosolic protein extracts, we fractionated cells and extracted the nuclear protein using a kit (Cat. No. 40010, Active Motif, Carlsbad, CA) supplemented with 1 × protease inhibitor cocktail, 1 mM PMSF, 10 mM NAM and 5 µM sirtinol. To immunoprecipitate endogenous HIF2α, we incubated extracts with a monoclonal human HIF2α antibody (Cat. No. NB100132, Novus Biologicals) for 1 h and then immunoprecipitated using magnetic protein G beads (Cat. No. 54002, Active Motif). We immuno blotted for endogenous HIF2α or acetyl lysine as described 13, 16 .
For shortchain fatty acid (SCFA) experiments, we cultured a single 60mm plate of Hep3B cells for 2 h in complete medium with 5 µM sirtinol plus 10 mM NAM under normoxia and then incubated for 4 h with medium containing vehicle, sodium acetate, sodium proprionate or sodium butyrate with 5 µM sirtinol plus 10 mM NAM. For conditioned medium experiments, we cultured a single 60mm plate of Hep3B cells for 4 h under normoxia in complete medium supplemented with 5 µM sirtinol plus 10 mM NAM and then incubated for an additional 2 h under either normoxia (control medium) or hypoxia (conditioned medium). We replaced 2 mL of cell medium of normoxiamaintained Hep3B cells (cultured for 4 h in complete medium with 5 µM sirtinol plus 10 mM NAM) with either 2 mL of control or conditioned medium and incubated the cells for 2 h. We then prepared wholecell extracts for immunoblotting of endogenous HIF2α or acetyl lysine.
For transient transfection siRNA knockdown experiments, we first trans fected Hep3B cells in a single 60mm plate with siRNA, maintained the transfected cells in complete medium for 42 h under normoxia, changed medium to complete medium with 5 µM sirtinol plus 10 mM NAM, maintained cells for another 6 h under normoxia, exposed cells to the indicated condition and then prepared wholecell extracts for immunoblotting of endogenous HIF2α or acetyl lysine.
For lentiviral knockdown (control, Acss2) and knockdown/rescue (WT and MUT Acss2) experiments, 36 h after changing from polybrenecontaining medium to complete medium (42 h after initial viral transduction), we cultured a single 60mm plate of Hep3B cells for 2 h in complete medium with 5 µM sirtinol plus 10 mM NAM under normoxia and incubated for 4 h with medium containing vehicle or sodium acetate with 5 µM sirtinol plus 10 mM NAM. We then prepared wholecell extracts for immunoblotting of endogenous HIF2α or acetyl lysine.
Ectopic HIF-2a acetylation (cells).
We housed a single 60mm plate of stably transformed Hep3B cells expressing WT K3 or R3 HIF2α under normoxia for 6 h in complete medium containing 5 µM sirtinol plus 10 mM NAM and then transferred cells to either normoxia or hypoxia for the indicated period. At the end of the incubation period, we lysed cells with CytoBuster protein extraction reagent supplemented with 1× protease inhibitor cocktail, 1 mM PMSF, 10 mM NAM and 5 µM sirtinol. We purified ectopic HAtagged HIF2α by HAagarose pulldown, then immunoblotted using antibody recognizing acetylated lysine, followed by immunoblotting using antibody recognizing the HA epitope as previously described 13, 16 .
Endogenous HIF-2a acetylation (mice). We lysed mouse liver (~50 mg) or kidney samples (~100 mg) at the time of harvest in 0.5 mL CytoBuster protein extraction reagent supplemented with 1× protease inhibitor cocktail, 1 mM PMSF, 10 mM NAM and 5 µM sirtinol. We incubated protein extract (500 µg) with a monoclonal human HIF2α antibody for 1 h to bind endogenous HIF2α protein and immunoprecipitated the complex using magnetic protein G beads (Cat. No. 54002, Active Motif). We then immunoblotted for endogenous HIF2α or acetyl lysine as described 13, 16 .
Immunoprecipitation experiments (cells).
We immunoprecipitated endog enous HIF2α proteins from a single 100mm plate of Hep3B cells using a Universal Magnetic CoIP kit (Cat. No.54002, Active Motif) according to the manufacturer's protocol. We first incubated wholecell extracts (500 µg) with magnetic protein G beads. We then incubated the cleared super natants with antibodies to HIF2α (endogenous) or HA (rescue HIF2α pro tein), or with normal mouse IgG (Cat. No. sc2025, Santa Cruz Biotechnology) for 2 h before addition of magnetic protein G beads. After binding, we pelleted beads by centrifugation. After washing, we eluted the immuno precipitated proteins and immunoblotted with antibodies to human p300 (1:500 dilution; Cat. No. sc584, Santa Cruz Biotechnology), human CBP (1:500 dilution; Cat. No. 4772, Cell Signaling Technology) or HIF2α (1:1,000 dilution; Cat. No. NB100132, Novus Biologicals).
In vitro immunoprecipitation experiments (extracts).
We first transfected Hep3B cells in a single 100mm plate with siRNA, waited 48 h, exposed cells to the indicated condition and prepared wholecell extracts using a Universal CoIP Kit (Cat. No. 54002, Active Motif) as described 13 . For hypoxia samples, we performed all initial extract preparations in the hypoxia workstation. For all subsequent in vitro experiments, we performed manipulations under nor mal oxygen conditions. We next added acetyl CoA (final concentration 50 µM; Cat. No. A2056, Sigma), ATP (final concentration 100 µM; Cat. No. FLAAS1VL, Sigma) or acetate (final concentration 50 µM; Cat. No. A2056, Sigma) to 50 µl wholecell extract and incubated the extract at 30 °C for 30 min. We then immu noprecipitated endogenous HIF2α and performed immunoblotting for HIF2α, CBP or p300 as described 13, 16 .
Real-time PCR analyses. We determined the expression of endogenous EPO, VEGFA, SERPINE1, MMP9, SLC2A1, PGK1 and PPIB from a single pooled sample made from three individually transfected wells (biological replicates) of Hep3B cells in a 12well plate for each condition or of endogenous Epo and Ppib from the indicated number of individual mouse organs (biological replicates). npg treatment group, we first selected mice according to an acceptable range of ane mia (~21-24%). We then subdivided mice into groups of 5 mice (plus up to 3 extra mice to allow for losses or harvesting of mice during the protocol) for every collection day with similar starting mean hematocrit levels for each group (see Supplementary Table 1 ). We gavaged anemic mice per os (p.o.) with vehicle (water), glyceryl triacetate (GTA; 90 µL/25 g body weight; Cat. No. W200700, SigmaAldrich Chemicals, Saint Louis, MO) glyceryl tributyrate (GTB; 140 µL/25 g body weight; Cat. No. W222305, Sigma) or glyceryl tripropionate (GTP; 115 µL/25 g body weight; Cat. No. W328618, Sigma) using a 20gauge stainless steel animal feeding tube (Cat. No. FTSS20S25, Instech Solomon). We performed gavage once a day in the morning from day 4 to day 20 until euthanasia. We euthanized mice and harvested organs for further characteriza tion on days 4, 7, 10, 13, 16 and 20 after the initial PHZ injection, corresponding to days 0, 3, 6, 9, 12 and 16 of gavage. We gave a control treatment group (solvent injection), which had approximately equal baseline hematocrits (~49%), acetate (GTA) or vehicle (water) by oral gavage once a day starting on day 4 following solvent injection and we harvested the mice on days 4, 7, 10, 13, 16 and 20 after the initial solvent injection. We noted no differences in hematocrit levels in this control group (data not shown).
For intraperitoneal (i.p.) shortchain fatty acid (SCFA) treatments, we pre pared a sterile 0.5 M stock solution of each SCFA using sterile PBS and filtersterilized using a 0.2 µM filter (Cat. No. 1902520, Thermo Scientific). We injected mice intraperitoneally with the indicated SCFA/PBS or vehicle (sterile PBS alone) solution. We did not blind investigators as to PHZ or gavage treatments because of institutional animal monitoring requirements, although we performed harvesting and blood draws of mice using only eartag identifiers. The University of Texas Southwestern Medical Center Institutional Animal Care and Use Committee approved all experiments.
Mouse experiments: chronic renal failure. Prior to nephrectomy, we collected blood by eye bleeds for baseline hematocrit, plasma creatinine and blood urea nitrogen (BUN). We performed 5/6 nephrectomy on wildtype CD1 female mice (n =49, 6 weeks old, 25-28 g; Charles River, Strain Code 022) 31 . Four weeks after nephrectomy, we again collected blood and plasma from the surviving mice (n = 33) for analysis. We excluded CRF mice with hematocrits less than 21% or greater than 25%. We supplemented three groups of CRF mice, which exhibited approximately equal composite hematocrit, plasma creatinine and plasma BUN means (see Supplementary Table 1) , with vehicle alone (Group A), cyclically administered acetate or vehicle (Group B) or a single week of short chain fatty acids (Group C). For supplements, we administered 400 µL of a sterile 0.5 M stock solution of either PBS (vehicle), sodium acetate/PBS (A, Ac, NaAc), sodium butyrate/PBS (B, Bu, NaBu) or sodium propionate/PBS (P, Pr, NaPr) by thriceweekly (Monday, Wednesday, Friday) intraperitoneal singledose injections at approximately 9 a.m. on the day of treatment for the indicated periods. For cyclical acetate supplementation of CRF and DH Kitmutant mice, acetate supplementation was administered for 2 weeks following baseline measurements, was held for 1 week (DH Kitmutant mice) or 2 weeks (CRF mice) and finally was resumed for an additional 2 weeks. We obtained hemato crits via eye bleeds on the Monday of each week, before supplementation or as indicated. After completion of the treatment protocol, we harvested blood and kidneys for further characterization after euthanasia. The University of Texas Southwestern Medical Center Institutional Animal Care and Use Committee approved all experiments.
Mouse experiments: double-heterozygous Kit mutant. We obtained male and female doubleheterozygous (DH) Kitmutant mice (Kit W /Kit W−v ) on a WBB6 F1 hybrid background (Jackson Laboratories, Stock No. 100410) as well as wild type gender and agematched controls from the same colony and housed mice under standard conditions. For treatments, we obtained baseline hematocrits via eye bleeding from 8weekold mice, and we then administered 400 µL of a sterile 0.5 M stock solution of either PBS (vehicle), sodium acetate/PBS (A, Ac, NaAc), sodium butyrate/PBS (B, Bu, NaBu) or sodium propionate/PBS (P, Pr, NaPr) for the indicated periods as thriceweekly (Monday, Wednesday, Friday) intraperitoneal injections as a single dose at approximately 9 a.m. on the day of treatment. After completion of the treatment protocol, we harvested blood and kidneys for further characterization after euthanasia. The University of Texas Southwestern Medical Center Institutional Animal Care and Use Committee approved all experiments.
Immunohistochemistry. We fixed tissues used for immunohistochemical anal yses in 10% neutralbuffered formalin, paraffinembedded and sectioned at 5 µm. We mounted sections on polyllysine-coated glass slides, baked at 56 °C for 30 min, deparaffinized in xylene and rehydrated through graded alcohols. We quenched endogenous peroxidase activity by incubating slides in 3% hydrogen peroxide (Cat. No. H1009100ML, Sigma) in deionized water for 30 min and rinsing in deionized water twice for 5 min. For Acss2 antibody (Cat. No. 3658, Cell Signaling Technology) staining, we incubated slides with the BD Retrievagen A working solution (Cat. No. 550524, BD Biosciences, San Jose, CA) and heated to ~90 °C (193 °F) in a microwave oven for 10 min, followed by slow cooling to room temperature over 60 min. We then rinsed slides twice with deionized water and next rinsed once with PBS for 10 min. We blocked nonspecific binding by incubation with 10% goat serum (Cat. No. S1000, Vector Laboratories, Burlingame, CA) in PBS for 60 min. Next, we incubated slides with Acss2 primary antibody (1:150 in 10% goat serum with PBS) overnight at 4 °C and then with biotinconjugated goat antirabbit IgG (1:500 in 10% goat serum with PBS) for 2 h. After rinsing in PBS, we incubated slides with HRPconjugated streptavadin (1:750 in 10% goat serum with PBS) for 60 min at room temperature. After rinsing in PBS, we visualized immunoreactive deposits by incubation with 3′amino9ethylcarbazole (Cat. No. 002007, Invitrogen) for 10 min (kidney sections) or 15 min (liver sections). Finally, we counterstained slides with hematoxylin QS (Cat. No. H3404, Vector Laboratories) for 2 min and coverslipped using AquaPolymount (Cat. No. 18606, Polysciences, Inc.).
Plasma Epo protein measurements. To harvest plasma, we mixed 200 µL eye blood with 7.8 µL heparin (Cat. No. NC9593879, Fisher Scientific), incubated 30 min on ice and spun down at 14,000g for 10 min. We then removed the supernatant and stored in −80 °C until analysis. For plasma Epo protein measurements, we assayed 25 µL of plasma in duplicates using a Mouse Erythropoietin Quantikine ELISA Kit (Cat. No. MEP00B, R&D Systems).
Plasma chemistry, hematocrit and reticulocyte measurements. To measure creatinine and blood urea nitrogen (BUN), we divided 50 µL plasma into two aliquots and measured in duplicates using a Vitros 250 Chemistry System machine (OrthoClinical Diagnostics, Inc.) with VITROS CREA or VITROS BUN/UREA slides running on VITROS Chemistry System performed in the University of Texas Southwestern Medical Center Mouse Metabolic Phenotyping Core Facility.
We obtained spun hematocrits from tailvein or eye bleeds 11 . For reticulocyte measurements, we obtained dried blood smears and stained using new meth ylene blue solution (0.5 g new methylene blue, 1.4 g potassium oxalate, 0.8 g sodium chloride brought to 100 mL using deionized water and filtered using a 0.45µm filter). We stained slides for 10 min, rinsed three times in PBS for 5 min each and then coverslipped. We counted cells and reticulocytes in three fields chosen at random (40× magnification, ~500 to 1,000 cells/field) and summed to determine reticulocyte percentage.
Statistical analyses. As we collected molecular and biochemical data for the role of acetate/ACSS2 switch in regulation of HIF2 signaling and EPO regulation in Hep3B cells, we anticipated a similar role for the acetate/Acss2 switch in mice. Therefore, we considered the mouse experiments as exploratory studies aimed at identifying a meaningful biological role for acetate and Acss2 in Hif2 sig naling and Epo regulation. Accordingly, we were interested in sample sizes that allowed for detection of a very large effect size 69, 70 . We used oneway statistical testing in anticipation of similar results in mice as we noted in Hep3B cells. We chose α = 0.10 and β = 0.20 as an acceptable type I and type II statistical error, respectively, and therefore set power = 0.80. Given the small sample size, we performed testing for both normal as well as nonnormal distributions, but we only reported statistics for normal distributions.
We used GraphPad Prism and StatPlus to analyze data by Student's ttest or MannWhitney Utest for two group comparisons and by oneway or twoway ANOVA for multiple comparisons followed by Tukey's or Dunnett's correction to provide coverage for type I statistical error. When one group was used as a npg
